ClinicalTrials.gg
TerminatedNCT04419389R/RUpdated Mar 17, 2025Results posted

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

A Phase 1/2 interventional study of APR-246 (eprenetapopt) + Acalabrutinib in CLL and APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL in Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by Aprea Therapeutics. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.

Primary conditionLymphoma, Mantle-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. The study's listed conditions name Lymphoma, Mantle-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aprea Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 905 studies in Lymphoma, Mantle-Cell with a site in United States — 81 open to participants now, 149 under way, 7 of them phase 3. Lymphoma, Mantle-Cell · United States.

Enrollment
742nd of 777
1 · median 35
Started
2021
with 28 others
Phase 1/2
127 of 905
15 open now
Registered
783rd of 905
by date

Among the 905 studies in Lymphoma, Mantle-Cell with a site in United States, this one is the 742nd largest by enrollment of the 777 interventional ones that give a count, is one of 29 that started in 2021, is one of 127 in phase 1/2, and was the 783rd registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

81 of the 905 studies in Lymphoma, Mantle-Cell with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Lymphoma, Mantle-Cell with a site in United States, or all of them as a file.
02

Study summary

Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.

Read the detailed description

Phase 1, open-label, dose-finding and cohort expansion study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 (eprenetapopt) in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.

The study includes a safety lead-in portion followed by an expansion portion in subjects with R/R CLL, Richter Transformation (RT), and R/R MCL.

03

Conditions studied

  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma

Keywords

  • APR-246
  • eprenetapopt
04

In context

Lymphoma, Mantle-Cell Reclassified

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

This study's enrollment of 1 is below the median of 37 across 1,003 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is able to understand and is willing and able to comply with the study requirements and to provide written .
  2. Documented histologic diagnosis of R/R CLL, RT, or R/R MCL
  3. Safety Lead-In Cohort 1: Patients whose most recent regimen did not include BTK inhibitor therapy.
  4. Safety Lead-In Cohort 2: Patients whose most recent regimen did not include Bcl-2 inhibitor therapy.
  5. Safety Lead-In Cohort 3: APR-246 + venetoclax + rituximab in patients with RT
  6. (or international normalized ratio) and partial thromboplastin time not to exceed 1.2 × the institution's normal range.
  7. Adequate BM function independent of growth factor or transfusion support, per local laboratory reference range at screening as follows:

    1. count ≥ 75 000/mm3;
    2. (ANC) ≥ 1000/mm3 unless cytopenia is clearly due to marrow involvement from CLL or MCL
    3. total ≥ 9 g/dL (without transfusion support within 2 weeks of screening);
  8. Adequate organ function as defined by the following laboratory values:

    1. ≥ 30 mL/min.
    2. Total serum ≤ 1.5 × (ULN) unless due to Gilbert's syndrome, NHL organ involvement, controlled immune hemolysis or considered an effect of regular blood transfusions.
    3. (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, unless due to NHL organ involvement.
  9. Age ≥18 years at the time of signing the informed consent form.
  10. (ECOG) performance status of 0, 1 or 2.
  11. Projected of ≥ 12 weeks.
  12. Women of and men with female partners of childbearing potential must be willing to use an effective form of .

Exclusion criteria

Exclusion Criteria:

  1. Patient with known allergies to xanthine oxidase inhibitors and/or rasburicase.
  2. For patients to receive rituximab on this protocol, prior allergy to rituximab is prohibited.
  3. No concomitant anticancer therapies, immunotherapies, cellular, or radiotherapy. No major surgery within 3 weeks prior to first dose of study treatment.
  4. Uncontrolled hemolytic anemia (AIHA) or immune thrombocytopenia.
  5. Consumption of grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting study treatment.
  6. Concomitant for disease related pain control are allowed at any dose but must be discontinued prior to any study treatment initiation. Chronic use of corticosteroids is allowed up to ≤ 20 mg prednisone daily for non-cancer related conditions at the time of study start.
  7. History of or autologous stem cell transplant (SCT) or CAR-T therapy within the last 30 days or with any of the following:
  8. Active (GVHD)
  9. Cytopenias from incomplete blood cell count recovery post-transplant;
  10. Need for anti-cytokine therapy for residual symptoms of neurotoxicity > grade 1 from CAR-T therapy;
  11. Ongoing therapy.
  12. Known history of (HIV) serum positivity.
  13. Active /C.
  14. Known central nervous system (CNS) involvement by lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided to sponsor.
  15. Known neurologic disorder or residual neurologic toxicities that may put patients at increased risk of neurologic toxicity in the opinion of the investigator.
  16. Cardiac abnormalities.
  17. Concomitant or previous malignancies with less than a 1 year disease- free interval at the time of signing consent.
  18. A female patient who is pregnant or breast-feeding.
  19. Active uncontrolled systemic infection.
  20. Received an agent within 30 days or within 5 T1/2, whichever is shorter prior to the first dose of study treatment.
  21. active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of ibrutinib or venetoclax.
  22. Current treatment with certain strong cytochrome P450 3A4 () inhibitors or inducers and/or strong P-gp inhibitors..
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Safety Lead-In Cohort 1

    APR-246 4.5 g/d + Acalabrutinib in Subjects with R/R CLL (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

    Drug: APR-246 (eprenetapopt) + Acalabrutinib in CLL

  • Experimental
    Safety Lead-In Cohort 2

    APR-246 4.5 g/d + Venetoclax + Rituximab in Subjects with R/R CLL (APR 246 Monotherapy Lead-in; 4.5 g/d x 2).

    Drug: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL

  • Experimental
    Expansion Cohorts

    APR-246 4.5 g/d + (Acalabrutinib, OR, (Ven+R)) in Subjects with R/R TP53-mutant CLL, and/or MCL, and/or RT

    Drug: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT

  • Experimental
    Safety Lead-In Cohort 3

    APR-246 4.5 g/d + Venetoclax + Rituximab in Subjects with RT

    Drug: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT

Interventions

  • DrugAPR-246 (eprenetapopt) + Acalabrutinib in CLL

    Drug page: EprenetapoptStudies of EprenetapoptEprenetapopt pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

  • DrugAPR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL

    Drug page: EprenetapoptStudies of EprenetapoptEprenetapopt pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

  • DrugAPR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT

    Drug page: EprenetapoptStudies of EprenetapoptEprenetapopt pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule

  • DrugAPR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT

    Drug page: EprenetapoptStudies of EprenetapoptEprenetapopt pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule

07

What researchers measure

Primary outcomes

  1. To Determine the DLT of APR-246 in Combination With Acalabrutinib or in Combination With Venetoclax + Rituximab Therapy in Subjects With NHL, Including Subjects With R/R CLL, RT and R/R MCL.

    The occurrence of DLTs, classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events .

    Time frame: Through study completion, approximately 1 year

  2. To Assess the Frequency of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Related to APR-246 in Combination With Acalabrutinib and With Venetoclax + Rituximab Therapy.

    The frequency of TEAEs and SAEs related to APR-246 in combination with acalabrutinib and with venetoclax + rituximab therapy

    Time frame: Through study completion, approximately 6 months

  3. To Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) in Subjects With TP53 Mutant NHL, Including Subjects With R/R CLL, RT and R/R MCL.

    The highest dose of APR-246 with acceptable toxicity (RP2D of APR-246) (the dose producing ≤ 20% of DLT).

    Time frame: Through study completion, approximately 1 year

08

Results

Posted Nov 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneSafety Lead-In Cohort 2
Started1
Completed0
Not completed1

Outcome measures

PrimaryTo Determine the DLT of APR-246 in Combination With Acalabrutinib or in Combination With Venetoclax + Rituximab Therapy in Subjects With NHL, Including Subjects With R/R CLL, RT and R/R MCL.

The occurrence of DLTs, classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events .

Time frame:
Through study completion, approximately 1 year

No measurements were reported for this outcome.

PrimaryTo Assess the Frequency of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Related to APR-246 in Combination With Acalabrutinib and With Venetoclax + Rituximab Therapy.

The frequency of TEAEs and SAEs related to APR-246 in combination with acalabrutinib and with venetoclax + rituximab therapy

Time frame:
Through study completion, approximately 6 months
Reported as:
Number · participants
To Assess the Frequency of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Related to APR-246 in Combination With Acalabrutinib and With Venetoclax + Rituximab Therapy.
participantsSafety Lead-In Cohort 2
To Assess the Frequency of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Related to APR-246 in Combination With Acalabrutinib and With Venetoclax + Rituximab Therapy.1
PrimaryTo Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) in Subjects With TP53 Mutant NHL, Including Subjects With R/R CLL, RT and R/R MCL.

The highest dose of APR-246 with acceptable toxicity (RP2D of APR-246) (the dose producing ≤ 20% of DLT).

Time frame:
Through study completion, approximately 1 year

No measurements were reported for this outcome.

Adverse events

Collected over approximately up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Lead-In Cohort 1———
Safety Lead-In Cohort 20/1 (0%)0/1 (0%)1/1 (100%)
Expansion Cohorts———
Safety Lead-In Cohort 3———
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSafety Lead-In Cohort 1Safety Lead-In Cohort 2Expansion CohortsSafety Lead-In Cohort 3
DizzinessNervous system disorders—1/1——
Blood Bilirubin IncreasedInvestigations—1/1——
BursitisMusculoskeletal and connective tissue disorders—1/1——
ConstipationGastrointestinal disorders—1/1——
Odema PeripheralGeneral disorders—1/1——
HyperphosphatemiaGeneral disorders—1/1——
InsomniaPsychiatric disorders—1/1——
Muscular Weakness Lower LimbMusculoskeletal and connective tissue disorders—1/1——
Nasal CongestionRespiratory, thoracic and mediastinal disorders—1/1——
PainGeneral disorders—1/1——

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Lead-In Cohort 2
Median74 (74 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Safety Lead-In Cohort 2
Female1
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety Lead-In Cohort 2
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Safety Lead-In Cohort 2
United States1
09

Study locations

4 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Aug 2021, 5 months.

Results were first posted in Nov 2024, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 5, 2020
StartActual
Mar 2, 2021
Primary completionActual
Aug 23, 2021
CompletionActual
Aug 24, 2021
Results first posted
Nov 15, 2024
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04419389
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Mar 2, 2021
Primary completion
Aug 23, 2021
Completion
Aug 24, 2021
Results posted
Nov 15, 2024
Last update
Mar 17, 2025

Study contacts

Joachim Gullbo, MD
study director · Theradex Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eprenetapopt

Start the discussion